57.76
+1.96(+3.51%)
Currency In USD
Address
200 Arsenal Yards Boulevard
Watertown, MA 02472
United States of America
Phone
857 285 5300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
208
First IPO Date
August 21, 2020
| Name | Title | Pay | Year Born |
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, Chief Executive Officer & Director | 1.23M | 1979 |
| Dr. Bruce L. Booth DPHIL, Ph.D. | Co-Founder & Independent Chairman | 70,000 | 1974 |
| Ms. Ellen V. Chiniara Esq., J.D. | Chief Legal Officer & Corporate Secretary | 696,080 | 1959 |
| Dr. Jeremy G. Chadwick Ph.D. | Chief Operating Officer | 719,400 | 1963 |
| Mr. Bruce N. Jacobs CFA | Chief Financial Officer | 754,540 | N/A |
| Dr. Jared A. Gollob M.D. | Chief Medical Officer | 768,400 | 1965 |
| Mr. Noah Goodman M.B.A. | Chief Business Officer | 0 | 1987 |
| Dr. Juliet Williams B.A Ph.D. | Head of Research | 0 | N/A |
| Ms. Justine E. Koenigsberg | Vice President of Investor Relations | 0 | N/A |
| Ms. Karen Weisbach | Head of People & Culture | 0 | N/A |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.